GeneDx Holdings (WGS) Debt to Equity (2020 - 2025)
GeneDx Holdings (WGS) has disclosed Debt to Equity for 6 consecutive years, with $0.16 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity fell 26.15% to $0.16 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.16, a 26.15% decrease, with the full-year FY2025 number at $0.16, down 26.15% from a year prior.
- Debt to Equity was $0.16 for Q4 2025 at GeneDx Holdings, down from $0.18 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.27 in Q2 2024 to a low of -$0.04 in Q1 2021.
- A 5-year average of $0.11 and a median of $0.04 in 2022 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: soared 1173.55% in 2024, then crashed 30.64% in 2025.
- GeneDx Holdings' Debt to Equity stood at $0.04 in 2021, then grew by 10.53% to $0.04 in 2022, then soared by 495.59% to $0.23 in 2023, then decreased by 8.39% to $0.21 in 2024, then fell by 26.15% to $0.16 in 2025.
- Per Business Quant, the three most recent readings for WGS's Debt to Equity are $0.16 (Q4 2025), $0.18 (Q3 2025), and $0.19 (Q2 2025).